Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients Biogen has announced that the first patient with spinal muscular atrophy (SMA) has been treated with Spinraza (nusinersen), who were prio...
Lynparza was approved for three more indications in Japan AstraZeneca and Merck announced that Lynparza (olaparib) was approved for three more indications in Japan. The three new cancer indicatio...
Kite’s CAR-Tcell therapy received approval in Europe for relapsed or refractory mantle cell lymphoma Kite announced that it received conditional approval in Europe for Tecartus (brexucabtagene autoleucel). Tecartus is a chimeric antigen r...
Governments and other organizations raised US$ 8.8 billion at Global Vaccine Summit The Global Vaccine Summit hosted in the UK was successful in raising US$ 8.8 billion, more than the expected target of US$ 7.4 billion. T...
